These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20492876)

  • 1. [Intermittent use of etanercept in psoriasis].
    Herrera E; Alcaide AJ
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():18-25. PubMed ID: 20492876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence.
    Strohal R; Chimenti S; Vena GA; Girolomoni G
    J Dermatolog Treat; 2013 Jun; 24(3):199-208. PubMed ID: 22812568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent etanercept therapy in pediatric patients with psoriasis.
    Siegfried EC; Eichenfield LF; Paller AS; Pariser D; Creamer K; Kricorian G
    J Am Acad Dermatol; 2010 Nov; 63(5):769-74. PubMed ID: 20833444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial).
    Strohal R; Puig L; Chouela E; Tsai TF; Melin J; Freundlich B; Molta CT; Fuiman J; Pedersen R; Robertson D
    J Dermatolog Treat; 2013 Jun; 24(3):169-78. PubMed ID: 22251226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up.
    Puig L; Camacho Martínez FM; Gimeno Carpio E; López-Ávila A; García-Calvo C
    Dermatology; 2012; 225(3):220-30. PubMed ID: 23235195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
    N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study.
    Daudén E; Griffiths CE; Ortonne JP; Kragballe K; Molta CT; Robertson D; Pedersen R; Estojak J; Boggs R
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1374-82. PubMed ID: 19563497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
    Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
    J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis.
    Esposito M; Gisondi P; Cassano N; Babino G; Cannizzaro MV; Ferrucci G; Chimenti S; Giunta A
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S31-4. PubMed ID: 25381971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long term efficacy and safety of etanercept in psoriasis].
    García-Patos Briones V; Mollet Sánchez J
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():12-7. PubMed ID: 20492875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study Group.
    Cassano N; Loconsole F; Miracapillo A; Travaglini M; Digiuseppe MD; Congedo M; Galluccio A; Buquicchio R; Mastrandrea V; Filieri M; Raho G; Pezza M; Vena GA
    Int J Immunopathol Pharmacol; 2010; 23(3):797-802. PubMed ID: 20943050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
    Gordon KB; Gottlieb AB; Leonardi CL; Elewski BE; Wang A; Jahreis A; Zitnik R
    J Dermatolog Treat; 2006; 17(1):9-17. PubMed ID: 16467018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept: efficacy and safety.
    Jiménez-Puya R; Gómez-García F; Amorrich-Campos V; Moreno-Giménez JC
    J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):402-5. PubMed ID: 19210697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
    Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B
    Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.